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Lonely No More: p53 Finds Its Minireview
Kin in a Tumor Suppressor Haven
Moshe Oren p73 transcript (Kaghad et al., 1997) and contains only
499 residues. With the exception of the last five residues,Department of Molecular Cell Biology
The Weizmann Institute of Science which are unique to p73b, the rest of the protein is
identical to the corresponding region in p73a. EvenRehovot 76100
Israel though the two forms appear todiffer in some properties
(see below), there isno indication so far that their expres-
sion is differentially regulated (Kaghad et al., 1997).
What do we learn from the p73 protein sequence?Oncogenes and tumor suppressor genes often come in
Remarkably, the conservation of the core DNA-bindingfamilies. c-myc has N-myc and L-myc as cousins,
domain shows a 63% identity with p53 (Figure 1). ThereH-ras has K-ras and N-ras, and Rb has p107 and p130.
is also a striking conservation of critical residues which,It was thus only logical to expect the same for p53, a
in p53, either interact directly with target DNA or arepivotal tumor suppressor gene which is the most fre-
required for the proper folding of the entire domainquent target for genetic alterations in human cancer (for
(Kaghad et al., 1997). The pivotal role of these particularrecent reviews, see Gottlieb and Oren, 1996; Ko and
residues is highlighted not only by direct structural stud-Prives, 1996; Oren and Prives, 1996; Levine, 1997). How-
ies (Cho et al., 1994), but also by the fact that they areever, p53 repeatedly defied these expectations: all at-
major hot spots for mutation in human cancer. Basedtempts to find 53-related genes, by low stringency hy-
on this striking similarity, one might predict that not onlybridization or by degenerate PCR techniques, came up
will p73 bind to DNA, but it may recognize DNA targetsempty-handed. This has led to the firm conviction that
very similar to those of p53.a p53 gene family does not exist.
Significant conservation also exists within the otherThis convictionÐperhaps one of the few that was
two main functional domains. This is less pronouncedagreed upon by the p53 fieldÐis no longer correct. A
within the N-terminal transactivation domain. However,novel gene has now been described whose products
one should recall that the amino acid sequence of thedisplay striking structural and functional resemblance
latter is rather poorly conserved even between humanto those of p53 (Kaghad et al., 1997). Moreover this
and murine p53; what is conserved between species,gene, termed p73 (big brother of p53?), may also be a
the overall acidic nature of the transactivation domain,tumor suppressor gene, perhaps one long sought-after
is also maintained in p73.in neuroblastoma and other cancers.
All theabove suggest that p73, like p53, is a sequence-p73 started off as an ugly ducklingÐa false positive
specific transactivator, which probably requires oligo-cDNA clone in a screen for mediators of insulin signaling
merization, and is likely to regulate genes that at least(Kaghad et al., 1997). However, as soon as its sequence
partially overlap those targeted by p53. Strong supportwas obtained, its swan-like charm emerged.
exists for some, though presently not all, of these predic-p73ÐA Structural and Functional Homolog of p53
tions. Analysis by the yeast two-hybrid assay revealedThe last decade has yielded extensive information on
that p73b can homo-oligomerize as efficiently as p53p53. Biologically, thebest known activities of p53 are cell
(Kaghad et al., 1997). Surprisingly, perhaps, p73a failedgrowth arrest and induction of apoptosis. Both probably
to form homotypic interactions. Moreover, the experi-require activation of latent p53 by incoming signals, of-
ments suggest a significant, albeit relatively weak, inter-ten coupled with a substantial increase in overall cellular
action between p73b and p53. It will be interesting top53 levels.
see whether mixed oligomers indeed exist in cells, andHuman p53 comprises 393 amino acid residues (Fig-
how this affects the biochemical and biological activitiesure 1). It includes three main functional domains: an
of p53.N-terminalacidic transactivation domain (TAD), a central
More importantly, p73 overexpression can trigger atDNA-binding core domain (DBD), and a C-terminal
least one canonical p53 target gene, p21Waf1. The p21Waf1homo-oligomerization domain (OD). All three domains
gene is strongly induced by p53 in many cell types (El-are required for efficient binding of p53 to recognition
Deiry et al., 1993). The p21 protein is a potent inhibitorsites within its physiological target genes and for tran-
of cyclin-dependent protein kinasesÐthedriving motorsscriptional activation of these genes.
of the cell cycleÐand augmented levels of p21 halt cellFive evolutionarily conserved boxes (I to V in Figure
cycle progression. It is thus not surprising that p21 is a1) were identified through comparison of p53 sequences
key effector, though not the only one, of p53-mediatedfrom various vertebrates. Four of these are in the central
growth arrest (Figure 2).DNA-binding core domain. Importantly, thevast majority
As shown now, p73 overexpression also induces p21of tumor-associated p53 missense mutations occur
(Kaghad et al., 1997; Table 1). Cells transiently trans-within this core domain, often in boxes II to V. Such
fected with a p73a expression plasmid display markedlymutant proteins usually fail to trigger transcription of
elevated levels of p21, comparable to those obtainedp53 target genes, resulting in loss of tumor suppressor
with wild-type p53. Importantly, p21 induction is abol-activity.
ished when a single Arg residue at position 292 of p73The newly discovered human p73 gene encodes two
is mutated to His; this residue is analogous to Arg 273distinct polypeptides (Figure 1). The longer one, denoted
p73a, comprises 636 residues. The shorter form, de- of human p53, which is often mutated in human cancer
and whose conversion to His abrogates the ability of p53noted p73b, arises through alternative splicing of the
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Figure 1. Comparison between the Human
p73 and p53 Proteins
p73a and p73b denote two forms derived
through alternative splicing. The black bar at
the C-terminal end of p73b identifies a stretch
of five residues not shared with p73a. The
five evolutionarily conserved blocks in p53
are labeled I to V. The positions of the Mdm2
binding motif and the nuclear localization sig-
nal (NLS) of p53 are also indicated, as well
as the following p53 protein domains: TAD,
transactivation domain, residues 1±42; DBD,
DNA-binding domain, residues 113±290; OD,
oligomerization domain, residues 330±360.
The percentage amino acid sequence identity
between p53 and p73 within each domain is
indicated.
to activate relevant target genes. Hence, p73 appears to p73ÐA Long Sought-after Tumor Suppressor Gene?
The similarity to p53 provided one provocative clue thatduplicate faithfully the transcriptional function of p53 on
at least one critical target gene. p73 may be a new tumor suppressor gene. The other
clue came when the p73 gene was mapped to the sub-Given the centrality of p21 in the p53 pathway (Figure
2), it was not surprising that, like p53, p73 is also capable telomeric p36 region of human chromosome 1 (Kaghad
et al., 1997). Deletions near the tip of the short arm ofof blocking cell proliferation when overexpressed. In a
standard stable transfection assay, p73 effectively chromosome 1, spanning 1p36, are common in a variety
of human tumors including neuroblastoma, colon can-blocked colony formation (Kaghad et al., 1997; Table 1).
This can be taken as preliminary evidence that p73 has cer, melanoma, and breast cancer (Schwab et al., 1996).
This observation has spurred an intensive search forattributes of a tumor suppressor, at least in this in vitro
assay. tumor suppressor genes in this chromosomal region.
Recent studies suggest that this region contains at leastInduction of apoptosis by p53 is less well understood.
Most probably, it also involves activities of p53 distinct two, and perhaps more, distinct tumor suppressor
genes (Versteeg et al., 1995; Schwab et al., 1996). Onefrom transactivation of specific target genes (Gottlieb
and Oren, 1996; Ko and Prives, 1996; Levine, 1997). At putative tumor suppressor gene appears to be selec-
tively deleted and presumably inactivated in neuro-present, it is impossible to tell whether p73 also pos-
sesses such activities (Table 1). Nevertheless, tran- blastomas that harbor amplification of the N-myc proto-
oncogene (Caron et al., 1995). Such tumors typicallyscriptional activation does play an important part in
p53-mediated apoptosis; genes that may serve as display large deletions in 1p; the critical tumor suppres-
sor gene appears to reside in region 1p35±36.1, proximaldownstream effectors have been identified (Figure 2). It
is conceivable that the ability of p73 to up-regulate p53 to the position of p73. Even more interesting, however,
is a second putative tumor suppressor gene, identifiedtarget genes is not limited to p21. Obvious questions are
whether p73 can up-regulate apoptosis-related genes in neuroblastoma tumors lacking N-myc amplification.
It has been tentatively mapped to 1p36.2±3, within ansuch as bax and Fas/Apo1, and whether p73 overex-
pression can cause apoptosis. 8 megabase (Mb) region. Importantly, p73 also resides
in this same region. A particular feature of this putativeIn summary, p73 looks very much like p53, and may
also work very much like p53. However, given the limited tumor suppressor gene is that it appears to be imprinted.
Thus, in tumors retaining only one copy of the corre-amount of available data, much more needs to be done
before the extent of overlap between the two can be sponding chromosomal region, this copy is almost al-
ways derived from the paternal chromosome. Thiscritically evaluated.
Figure 2. The p53 Pathway and the Putative
p73 Pathway
For a more detailed description, see Orenand
Prives, 1996.
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Table 1. Comparison of Reported Features of p53 and p73 one wishes to establish that p73 is a true tumor suppres-
sor gene, these critical issues will need to be resolvedActivity p53 p73
more rigorously. Until that time, p73 should simply be
Activation of p21Waf1 yes yes
regarded as a good candidate.Location (active form) nuclear nuclear
New Answers (Perhaps) to Old Questions,Growth arrest yes yes
and New Questions to Be AnsweredApoptosis yes ?
LOHa in cancer many cancers neuroblastoma The discovery of p73 sheds new light on a number of
Mutations in cancer very frequent none yet well-known facts about p53. One of the most obvious
Germline mutations Li-Fraumeni none yet is the almost normal developmentof p53 knock-out mice
syndrome
(Donehower et al., 1992). Given the numerous reportsDown-regulation yes ?
about the role of p53 in differentiation, apoptosis, andby Mdm2
proliferation of cultured cells, the lack of dramatic devel-
aLOH, loss of heterozygosity. opmental phenotypes was rather disappointing. Al-
though some defects were later uncovered, they were
limited in scope and penetrance. With other key regula-
strongly suggests that the paternal locus is imprinted tory proteins, mild phenotypes of single knock-outs
and consequently transcriptionally silent. Thus, the loss were explained by functional redundancy with other
of only the maternal copy of the gene would be sufficient family members. However, such explanation could not
to practically render the cells negative for the corre- be offered for p53. Not until p73, that is. It may now be
sponding transcript and protein. Any serious contender proposed that p73 doubles up for p53, and only fails to
for the candidate gene should therefore first be found do so under conditions of genomic damage, where a
to be imprinted, and additionally be silent in tumor cells specific function of p53 becomes irreplaceable. Of note,
retaining only one allele. the main difference so far between p53 and p73 is that
At least at a first approximation, p73 appears to fulfill the latter protein is neither stabilized nor activated by
these requirements. First, there is clear evidence for DNA damage (Kaghad et al., 1997; see Figure 2). Hence,
monoallelic expression, as is expected of an imprinted it may not play a role in monitoring genomic damage. As
gene. A normally occurring polymorphism has been to the possibility that p73 substitutes for developmental
identified in the noncoding region of the p73 gene functions of p53, the answer is likely to come from
(Kaghad et al., 1997). Using this polymorphism, p73 crosses between p53 and p73 knock-outs. On a caution-
mRNA was analyzed in the peripheral blood cells of five ary note, now that p73 has been identified, there is no
heterozygous healthy individuals; in all cases, only one compelling reason to exclude the existence of additional
allele was found to be expressed, suggesting that the p53 family members. Such yet-to-be-uncovered genes
other one was imprinted. Moreover, in the single case are likely to complicate the genetic analysis.
so far where the origin of the p73 mRNA in normal cells Another observation that p73 may explain is that, un-
could be determined, it was derived predominantly if like most tumors, neuroblastomas very rarely carry p53
not exclusively from the maternal allele. Hence, p73 ap- mutations (Ohgaki et al.,1993). It could now beproposed
pears to be paternally imprinted, exactly as predicted that in the particular normal cells that give rise to neuro-
for the putative 1p tumor suppressor gene. Needless to blastoma it is p73, rather than p53, that performs the
say, one has to be extremely reserved about information crucial tumor suppressor job. Hence, once p73 is inacti-
coming from such a small number of samples, regarding vated, there will be no significant selective pressure to
it mainly as an incentive for obtaining more complete, inactivate p53 as well. The actual picture is, however,
unequivocal data. more complex. While the p53 gene remains wild-type
Analysis of tumor-derived cell lines also largely agrees in almost all neuroblastomas, the protein may be mis-
with the notion that p73 is a strong candidate for the placed: rather than being nuclear, it accumulates in the
ªrealº 1p tumor suppressor gene. In particular, extremely cytoplasm (Ostermeyer et al., 1996). It is presently con-
low levels of p73 mRNA were found in the majority troversial whether this is truly a functional inactivation
(4/6) of neuroblastoma cell lines harboring chromosome of p53, which blocks its ability to respond to stress
1p deletions (Kaghad et al., 1997). This stands in stark and maintain genomic integrity. Yet, if this cytoplasmic
contrast with lines derived from some other tumors and sequestration truly results in p53 incapacitation, it may
from neuroblastoma without a deletion in 1p, where eas- make the need to invoke p73 less obvious. Even so, one
ily detectable p73 expression was much more common. could still propose that it is the lack of functional p73
Hence, the p73 allele retained in these four neuro- protein that underlies the cytoplasmic retention of p53.
blastoma lines may indeed be imprinted. Moreover, in Future work should clarify this issue.
one of the two 1p deletion-positive neuroblastoma lines It is thus yet to be proven that p73 is truly the long
that retained p73 mRNA, no p73 protein was detectable. sought-after 1p tumor suppressor gene. In particular,
Nevertheless, the picture is not perfect. The main dis- one worries about the inability to find coding region
comforting observation is that despite extensive efforts, mutations in cell lines tested to date. This concern is
no mutations could be found within the remaining p73 strengthened by the knowledge that single point muta-
allele in tumor cells with 1p deletions. One might argue tions, analogous to those observed in p53 in human
that there is no real selective pressure for mutating p73 cancer, indeed suffice to abrogate the antiproliferative
if only the imprinted, nonexpressed allele is retained. effect of p73 (Kaghad et al., 1997). Given the high fre-
However, p73 is also wild-type in the one neuroblastoma quency of such mutations in p53, it is puzzling that
the same does not pertain to p73 (Table 1). While theline that expresses the protein abundantly. Clearly, if
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imprinted nature of the p73 locus offers a reasonable
explanation, it is equally possible that p73 just happens
to reside within a chromosomal region harboring a clus-
ter of imprinted genes, and the real tumor suppressor
gene may actually be one of p73's neighbors. To resolve
this important issue, one may either need to eventually
find some tumors, not necessarily neuroblastoma, that
bear inactivating mutations in p73, or else go systemati-
cally through the entire 8 Mb region and rule out all
neighboring genes one by one.
In its relatively short history, p53 research has already
seen a number of surprising twists. The discovery of
p73 may be another major turning point along this road.
Judging from past experience, it is quite safe to predict
that p73 will soon become the latest spin-off from p53
to develop into a ªhotº topic in its own right.
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